Johnson & Johnson stock price forecast: Mixed momentum signals as JNJ slides 3.15% to $237.65

Traders Union
All News
Financial News
Johnson & Johnson drops 3.15% today

Highlights

Johnson & Johnson has launched a direct-to-consumer platform targeting uninsured and out-of-pocket U.S. patients, expanding its pharmaceutical access.
Despite the new platform, JNJ shares remain under pressure amid broader selling in the pharmaceutical sector.
Technical signals are mixed, but the stock is likely to trade between $235 and $245 with immediate support at $236 and high probability of upward stabilization.

Access initiative expands direct sales as stock faces broad selling

Johnson & Johnson launched a website to sell some of its pharmaceuticals directly to U.S. patients who do not have insurance or who pay out of pocket. This initiative was intended to expand access to the company's drugs for consumers outside of traditional coverage networks, though price action has remained under broader selling pressure.

Mixed momentum signals diverge as price tests intraday lows

On the technical side, the Ichimoku Kijun level at $236.21 now serves as immediate support. Daily momentum indicators are mixed: the MACD gives a Strong Buy signal and the ADX points to continued bullish momentum, but the Stochastic RSI is in deep oversold territory while the RSI reads as a buy. The Commodity Channel Index is neutral, Bull/Bear Power reflects recent overbought conditions on the daily chart, and short-term timeframes show seller dominance. The Awesome Oscillator is neutral and does not confirm either direction. JNJ opened today with a clear downside gap and has declined 3.15%, with price near the session low and volatility elevated. Early intraday action points to renewed pressure after the open, highlighting a divergence between bullish momentum signals and the heavy short-term sell-off.

Sideways trade favored as bullish indicators support upward bias

Over the next five trading days, JNJ is expected to trade between $235.00 and $245.00, a range reflecting typical volatility relative to current levels. There is a very high probability (over 80%) of an upward move, based on strong Buy signals from weekly Moving Averages, RSI, ADX, and MACD. The baseline scenario envisions stabilization in a sideways range within these bounds. A bullish scenario develops if the price rallies above $243.00 to challenge last week's highs, while a bearish move may materialize if the price breaks below support near $236.00, exposing the 50-day average at $226.00.

Viktoras Karapetjanc, expert at Traders Union, sees Johnson & Johnson’s direct-to-consumer drug sales initiative as fundamentally positive for long-term access and brand strength. He notes that despite today’s selling pressure and short-term volatility, the technical picture remains supportive above the medium- and long-term moving averages. Momentum and sentiment signals are constructive, with a high probability of an upward move in the near term. He believes the current move reflects only a brief shakeout, not a change in the stock’s bullish structure. "As long as JNJ holds the $236.00 area, I see upside potential outweighing the short-term noise."

Last time, analysts noted that Johnson & Johnson maintained a strong bullish trend as the price traded well above major moving averages, with momentum indicators such as MACD and ADX confirming persistent buying pressure while the RSI approached overbought territory. However, divergences among oscillators and heightened volatility signaled elevated short-term pullback risk, with key resistance near $250 and dynamic support identified around $238.

Source of Data: JNJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.